Kahira Pharmaceuticals eyes EGP 145M net profit in FY 2021/2022
Updated 2/16/2021 11:47:00 AM
ArabFinance: Kahira Pharmaceuticals and Chemical Industries Company (CPCI) targets a net profit of EGP 145 million for the fiscal year (FY) 2021/2022, compared to EGP 122.87 million in the corresponding period of 2020/2021, according to the company’s statement to the Egyptian Exchange on February 16th.
The company also eyes revenues worth EGP 1.2 billion during the FY 2021/2022, compared to EGP 1.15 billion in the prior FY.
The listed company reported an 18% Year on Year increase in its net profit in the July-December period of 2020, recording EGP 67 million, compared to EGP 56.77 million in the same period of 2019.
Kahira Pharmaceuticals is an Egypt-based company involved in the manufacture and trade of pharmaceutical products for human and veterinary use.
